Browse SSTR5

Summary
SymbolSSTR5
Namesomatostatin receptor 5
Aliases SS-5-R; somatostatin receptor subtype 5; SS5R; SS5-R; Somatostatin receptor type 5
Chromosomal Location16p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane; Multi-pass membrane protein.
Domain PF00001 7 transmembrane receptor (rhodopsin family)
Function

Receptor for somatostatin 28 and to a lesser extent for somatostatin-14. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase. Increases cell growth inhibition activity of SSTR2 following heterodimerization.

> Gene Ontology
 
Biological Process GO:0000910 cytokinesis
GO:0002790 peptide secretion
GO:0002791 regulation of peptide secretion
GO:0007187 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger
GO:0009306 protein secretion
GO:0009755 hormone-mediated signaling pathway
GO:0009914 hormone transport
GO:0010817 regulation of hormone levels
GO:0015833 peptide transport
GO:0023061 signal release
GO:0030072 peptide hormone secretion
GO:0030073 insulin secretion
GO:0031960 response to corticosteroid
GO:0032465 regulation of cytokinesis
GO:0032467 positive regulation of cytokinesis
GO:0033500 carbohydrate homeostasis
GO:0038169 somatostatin receptor signaling pathway
GO:0038170 somatostatin signaling pathway
GO:0042593 glucose homeostasis
GO:0042886 amide transport
GO:0045787 positive regulation of cell cycle
GO:0046879 hormone secretion
GO:0046883 regulation of hormone secretion
GO:0048545 response to steroid hormone
GO:0050708 regulation of protein secretion
GO:0050796 regulation of insulin secretion
GO:0051302 regulation of cell division
GO:0051384 response to glucocorticoid
GO:0051781 positive regulation of cell division
GO:0071383 cellular response to steroid hormone stimulus
GO:0071384 cellular response to corticosteroid stimulus
GO:0071385 cellular response to glucocorticoid stimulus
GO:0071396 cellular response to lipid
GO:0071407 cellular response to organic cyclic compound
GO:0090068 positive regulation of cell cycle process
GO:0090087 regulation of peptide transport
GO:0090276 regulation of peptide hormone secretion
Molecular Function GO:0001653 peptide receptor activity
GO:0004994 somatostatin receptor activity
GO:0008188 neuropeptide receptor activity
GO:0008528 G-protein coupled peptide receptor activity
GO:0033218 amide binding
GO:0042277 peptide binding
GO:0042923 neuropeptide binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04024 cAMP signaling pathway
hsa04080 Neuroactive ligand-receptor interaction
Reactome R-HSA-373076: Class A/1 (Rhodopsin-like receptors)
R-HSA-418594: G alpha (i) signalling events
R-HSA-388396: GPCR downstream signaling
R-HSA-500792: GPCR ligand binding
R-HSA-375276: Peptide ligand-binding receptors
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
Summary
SymbolSSTR5
Namesomatostatin receptor 5
Aliases SS-5-R; somatostatin receptor subtype 5; SS5R; SS5-R; Somatostatin receptor type 5
Chromosomal Location16p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SSTR5 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolSSTR5
Namesomatostatin receptor 5
Aliases SS-5-R; somatostatin receptor subtype 5; SS5R; SS5-R; Somatostatin receptor type 5
Chromosomal Location16p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SSTR5 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSSTR5
Namesomatostatin receptor 5
Aliases SS-5-R; somatostatin receptor subtype 5; SS5R; SS5-R; Somatostatin receptor type 5
Chromosomal Location16p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SSTR5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.9980.341
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.1510.432
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 473.70.0265
729033130MelanomaallAnti-PD-1 (nivolumab) 262301
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 151101
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 111201
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.1250.772
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.1250.847
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.7910.0264
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SSTR5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86016.7-16.70.429
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSSTR5
Namesomatostatin receptor 5
Aliases SS-5-R; somatostatin receptor subtype 5; SS5R; SS5-R; Somatostatin receptor type 5
Chromosomal Location16p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SSTR5. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSSTR5
Namesomatostatin receptor 5
Aliases SS-5-R; somatostatin receptor subtype 5; SS5R; SS5-R; Somatostatin receptor type 5
Chromosomal Location16p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SSTR5. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SSTR5.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSSTR5
Namesomatostatin receptor 5
Aliases SS-5-R; somatostatin receptor subtype 5; SS5R; SS5-R; Somatostatin receptor type 5
Chromosomal Location16p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SSTR5. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSSTR5
Namesomatostatin receptor 5
Aliases SS-5-R; somatostatin receptor subtype 5; SS5R; SS5-R; Somatostatin receptor type 5
Chromosomal Location16p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SSTR5 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSSTR5
Namesomatostatin receptor 5
Aliases SS-5-R; somatostatin receptor subtype 5; SS5R; SS5-R; Somatostatin receptor type 5
Chromosomal Location16p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SSTR5 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSSTR5
Namesomatostatin receptor 5
Aliases SS-5-R; somatostatin receptor subtype 5; SS5R; SS5-R; Somatostatin receptor type 5
Chromosomal Location16p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SSTR5 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting SSTR5.
ID Name Drug Type Targets #Targets
DB00104OctreotideSmall MoleculeSSTR1, SSTR2, SSTR53
DB04894VapreotideSmall MoleculeSSTR2, SSTR5, TACR13
DB06663PasireotideSmall MoleculeSSTR1, SSTR2, SSTR3, SSTR54
DB06791LanreotideSmall MoleculeSSTR2, SSTR52
DB13985Lutetium Lu 177 dotatateSmall MoleculeSSTR1, SSTR2, SSTR3, SSTR4, SSTR55